ストックスクリーナーアプリを入手
117.36
4.89%
5.47
プレマーケット:
116.51
-0.85
-0.72%
前日終値:
$111.89
開ける：
$113.01
24時間の取引高:
104.48K
Relative Volume:
0.89
時価総額：
$2.22B
収益：
$152.42M
当期純損益:
$45.24M
株価収益率:
46.76
EPS:
2.51
ネットキャッシュフロー:
$6.97M
1週間 パフォーマンス:
+8.12%
1か月 パフォーマンス:
+2.37%
6か月 パフォーマンス:
+17.64%
1年 パフォーマンス:
+61.83%
1日の値動き範囲:
$112.53
$117.53
1週間の範囲:
$107.99
$117.53
52週間の値動き範囲:
$67.72
$129.90
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
名前
Ligand Pharmaceuticals Inc
セクター
電話
858-550-7500
住所
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
LGND を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
117.36 | 2.22B | 152.42M | 45.24M | 6.97M | 2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-03 | 開始されました | Oppenheimer | Outperform |
| 2024-07-30 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-04-14 | 再開されました | Stephens | Overweight |
| 2021-02-04 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-06 | 開始されました | Barclays | Overweight |
| 2020-03-24 | ダウングレード | Argus | Buy → Hold |
| 2020-03-10 | 開始されました | Guggenheim | Neutral |
| 2020-02-06 | 開始されました | The Benchmark Company | Buy |
| 2019-09-19 | アップグレード | Barclays | Equal Weight → Overweight |
| 2019-06-11 | 開始されました | Barclays | Equal Weight |
| 2019-05-03 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-03-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-10-29 | アップグレード | ROTH Capital | Neutral → Buy |
| 2018-10-02 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-09-11 | 繰り返されました | Argus | Buy |
| 2018-08-17 | 開始されました | Goldman | Neutral |
| 2018-08-08 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2018-06-21 | 開始されました | Argus | Buy |
| 2017-12-27 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-09-05 | 再開されました | H.C. Wainwright | Buy |
| 2016-10-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-08-05 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2016-03-11 | 開始されました | Sidoti | Buy |
| 2016-03-03 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Ligand Pharmaceuticals Inc (LGND) 最新ニュース
Burney Co. Grows Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
JPMorgan Chase & Co. Lowers Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Position Lowered by JPMorgan Chase & Co. - Defense World
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Average Recommendation of “Buy” by Brokerages - Defense World
LGND (Ligand Pharmaceuticals) Debt-to-EBITDA : 0.54 (As of Sep. 2024) - GuruFocus.com
Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price Crosses Above 200-Day Moving AverageShould You Sell? - MarketBeat
Don't Ignore The Insider Selling In Ligand Pharmaceuticals - Simply Wall St
Principal Financial Group Inc. Boosts Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Is Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Recent Price Movement Underpinned By Its Weak Fundamentals? - Simply Wall St
Jane Street Group LLC Sells 7,790 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Jane Street Group LLC Trims Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Octavio Espinoza Executes Sell Order: Offloads $244K In Ligand Pharmaceuticals Stock - Benzinga
Ligand Pharmaceuticals (NASDAQ:LGND) Updates FY 2024 Earnings Guidance - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) shareholders have earned a 59% return over the last year - Yahoo Finance
MML Investors Services LLC Makes New Investment in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Insider Sell Alert: Octavio Espinoza Sells Shares of Ligand Pharmaceuticals Inc (LGND) - GuruFocus.com
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) CFO Octavio Espinoza Sells 2,104 Shares - MarketBeat
Ligand Pharmaceuticals CFO Espinoza sells $244,850 in stock By Investing.com - Investing.com Canada
Benchmark maintains Buy on Ligand Pharma stock citing consistent financial performance - Investing.com Canada
Geode Capital Management LLC Acquires 22,495 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Holdings Raised by Geode Capital Management LLC - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Receives “Buy” Rating from Benchmark - Defense World
Benchmark Reaffirms Buy Rating for Ligand Pharmaceuticals (NASDAQ:LGND) - MarketBeat
Franklin Resources Inc. Has $9.79 Million Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Barclays PLC Has $4.35 Million Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Stifel Financial Corp Raises Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Holdings Lifted by HighTower Advisors LLC - Defense World
Wellington Management Group LLP Decreases Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
What is Zacks Small Cap's Forecast for LGND FY2025 Earnings? - MarketBeat
Zacks Small Cap Issues Optimistic Estimate for LGND Earnings - Defense World
Zacks Small Cap Has Strong Estimate for LGND FY2026 Earnings - MarketBeat
Fmr LLC Raises Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Ligand Pharmaceuticals: A Strong Growth Trajectory with Impressive Returns and Strategic Advancements - mediahousepress
LGND: 2025 View Calls for 17% Topline Growth - Zacks Small Cap Research
Ligand Pharmaceuticals' SWOT analysis: diversified royalty model drives stock growth - Investing.com Australia
Barclays Boosts Ligand Pharmaceuticals (NASDAQ:LGND) Price Target to $160.00 - MarketBeat
Ligand Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges By Investing.com - Investing.com South Africa
Ligand Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges - Investing.com India
BNP Paribas Financial Markets Sells 1,586 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals' SWOT analysis: royalty aggregator stock poised for growth - Investing.com
What is HC Wainwright's Estimate for LGND FY2025 Earnings? - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 6,031 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
The Manufacturers Life Insurance Company Sells 167 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand price target raised to $151 from $135 at Oppenheimer - Yahoo Finance
Ligand Pharmaceuticals Inc (LGND) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):